A Phase 1 Ascending Single and Multiple Oral Dose Study to Assess the Safety and Tolerability, Including Gastrointestinal Safety, Pharmacokinetics and Pharmacodynamics of ASP7657 in Caucasian Healthy Male and Female Subjects, Including a Food Effect Cohort
Phase of Trial: Phase I
Latest Information Update: 20 Oct 2015
Price : $35 *
At a glance
- Drugs ASP 7657 (Primary) ; Naproxen
- Indications Pain
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 26 Mar 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 15 Dec 2014 Planned End Date changed from 1 Feb 2015 to 1 May 2015, according to the ClinicalTrials.gov record.
- 15 Dec 2014 Planned primary completion date changed from 1 Feb 2015 to 1 May 2015, according to the ClinicalTrials.gov record.